{"entity":{"id":"immunocore","kind":"company","name":"Immunocore","aka":[],"tldr":"Inventor of the ImmTAC soluble TCR bispecific; tebentafusp was the first to improve survival in a solid tumour.","summary":"Immunocore, based in Abingdon and listed as IMCR, invented the ImmTAC soluble T-cell receptor bispecific, and its tebentafusp was the first drug of the format to improve survival in a solid tumour. Tebentafusp, sold as Kimmtrak, was proved in IMCgp100-202 in uveal melanoma; brenetafusp targets PRAME and is in the PRISM-MEL-301 phase 3 in melanoma; and IMC-R117C targets PIWIL1 in colorectal cancer. OnCo links it to melanoma and uveal melanoma, to PRAME as a target, to Oxford Cancer, and to the idea of antibodies that recognise mutant KRAS and p53 fragments displayed on the cell surface. Whether soluble TCR bispecifics can work in common solid tumours beyond uveal melanoma is the open question. Tebentafusp has its own page.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Immunocore","links":[{"label":"Official website","url":"https://www.immunocore.com"}],"tags":[],"related":[],"cancers":[],"sections":["immunotherapy"],"technologies":[],"targets":[],"drugs":["tebentafusp"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05549297","nct04262466","nct06840119"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Abingdon","country":"GB","companyType":"biotech","website":"https://www.immunocore.com","ticker":"IMCR","investors":[],"funding":[]},"route":"/companies/immunocore/","neighbours":{"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"drug":[{"id":"brenetafusp","kind":"drug","name":"Brenetafusp","route":"/drugs/brenetafusp/"},{"id":"tebentafusp","kind":"drug","name":"Tebentafusp","route":"/drugs/tebentafusp/"}],"trial":[{"id":"imcgp100-202","kind":"trial","name":"IMCgp100-202","route":"/trials/imcgp100-202/"},{"id":"nct06840119","kind":"trial","name":"Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers","route":"/trials/nct06840119/"},{"id":"prism-mel-301","kind":"trial","name":"PRISM-MEL-301","route":"/trials/prism-mel-301/"},{"id":"nct04262466","kind":"trial","name":"Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors","route":"/trials/nct04262466/"},{"id":"nct05549297","kind":"trial","name":"Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)","route":"/trials/nct05549297/"}],"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"uveal-melanoma","kind":"cancer","name":"Uveal melanoma","route":"/cancers/uveal-melanoma/"}],"target":[{"id":"prame","kind":"target","name":"PRAME","route":"/targets/prame/"}],"idea":[{"id":"idea-bio1-pmhc-bispecifics-public-drivers","kind":"idea","name":"Antibodies that see mutant KRAS and p53 fragments displayed on the cell surface","route":"/ideas/idea-bio1-pmhc-bispecifics-public-drivers/"}],"institution":[{"id":"oxford-cancer","kind":"institution","name":"Oxford Cancer (Oxford University Hospitals and University of Oxford)","route":"/institutions/oxford-cancer/"}]}}